Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for Alzheimer’s disease, bipolar disorder, major depressive disorder, and PTSD. Its pipeline includes AL001, a patented lithium ionic cocrystal designed for improved brain delivery and safety, and ALZN002, a cell-based immunotherapy vaccine targeting Alzheimer’s. The company licenses technology from the University of South Florida and focuses on advancing clinical trials to develop treatments with potential neuroprotective and disease-modifying effects.
This description was generated via AI from an annual report. Updated about 1 year ago.